Antinuclear antibody (ANA)

Pick Ordered or Not ordered to see the note.

Indicated when

• —Clinical signs or symptoms specifically suggestive of systemic lupus erythematosus (SLE) or another ANA-associated connective tissue disease: inflammatory arthritis affecting small joints, a malar or photosensitive rash, unexplained pleuritic or pericardial symptoms, unexplained cytopenias, or renal disease with no other explanation [1]
• —Used to support or exclude SLE once specific clinical suspicion exists, not as a general screen [1]

Not indicated when

• —As a screening test in patients without specific signs or symptoms of SLE [1]
• —Ordering ENA sub-serologies (anti-dsDNA, anti-Smith, anti-Ro/SSA, anti-La/SSB, etc.) as an independent first-line screen instead of a reflex test after a positive ANA with ongoing clinical suspicion

Why not

In patients without specific signs or symptoms of SLE, a positive ANA is more likely to reflect the substantial baseline prevalence of ANA positivity in the general population than to indicate lupus or another connective tissue disease: a US population study found antinuclear antibodies present in 13.8% of people aged 12 and older [2]. Because SLE itself is uncommon, a positive result in an unselected patient is much more likely to be a false lead than a true finding, generating anxiety, specialist referral, and further sub-serology testing that carries its own cost and interpretive burden [1].

Better first step

Reserve ANA testing for patients with specific clinical findings that raise concern for SLE or a related connective tissue disease (inflammatory arthritis, characteristic rash, unexplained cytopenias or renal disease, serositis). If ANA is positive with ongoing clinical suspicion, follow with specific sub-serologies (anti-dsDNA, ENA panel) and rheumatology referral rather than ordering these in parallel with a screening ANA.

Typical ND rationale

An ND may order ANA as part of a broader autoimmune or inflammation screen in a patient with fatigue, joint aches, or other nonspecific symptoms, reasoning that autoimmune disease is underdiagnosed and that a simple blood test can help rule it in or out early.

Ontario coverage & CONO orderability

OHIP status

insured

L544 'Antinuclear' is listed in the 2026 Schedule of Benefits for Laboratory Services (fluorescent antibody test, fee $6.42) with no restricting Essential Specifications paragraph identified, so it is insured when a physician orders it after clinically assessing the patient [3, 4]. The Schedule does not separately list ENA sub-serologies or anti-dsDNA antibody by name; whether these bill under L544, under L535 'Other antibody tests', or another code was not confirmed this session and is unverified. ND-ordered ANA testing is patient-paid regardless [5].

CONO orderable

Yes — CONO list #20

CONO list item 20 'Anti-Nuclear Antibody', blood specimen. The CONO list has no separate item for ENA sub-serologies (anti-dsDNA, anti-Smith, anti-Ro/SSA, anti-La/SSB) under any name searched; these are not independently ND-orderable in Ontario and would only be pursued through physician or specialist follow-up after a positive ANA.

Linked conditions

• Lupus (systemic lupus erythematosus) and what a positive ANA means ↗

Counselling script

“If you have specific findings that raise concern for lupus, such as a particular joint pattern, a photosensitive rash, unexplained low blood counts, or kidney involvement, ANA is the right first test, and I'll order it today. Without those features, I wouldn't add it, because about one in seven healthy people test positive for ANA anyway, so a positive result there is more likely to be a false lead than a true finding. If new symptoms develop, we can revisit this.”

Revisit if

• —New inflammatory joint symptoms, photosensitive rash, unexplained cytopenias, or renal findings develop
• —ANA positive: reassess for specific sub-serologies and rheumatology referral

References

1. [1]Canadian Rheumatology Association / Choosing Wisely Canada (2024). Rheumatology: Eleven Tests and Treatments to Question. linkCRA/Choosing Wisely Canada: don't order ANA as a screening test in patients without specific signs or symptoms of SLE
2. [2]NIEHS / University of Florida (NHANES analysis) (2012). Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. linkANA prevalence in the US population aged 12 and older was 13.8%
3. [3]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026) - L544 Antinuclear antibody. linkL544 Antinuclear is listed in the 2026 OHIP Schedule with no restriction identified
4. [4]Government of Ontario (e-Laws) (2026). Health Insurance Act, R.R.O. 1990, Reg. 552: General, s. 22 (insured laboratory services). linkInsured lab testing requires ordering by an authorized provider who has clinically assessed the patient
5. [5]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkTests ordered by anyone other than an authorized provider, including NDs, are not insured services